Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Investigating Lipid-Modulating Agents for Prevention or Treatment of Covid-19: Jacc State-Of-The-Art Review Publisher Pubmed



Talasaz AH1, 2, 3 ; Sadeghipour P4 ; Aghakouchakzadeh M1 ; Dreyfus I5 ; Kakavand H1 ; Ariannejad H2 ; Gupta A5, 6, 7 ; Madhavan MV5, 6 ; Van Tassell BW3, 8 ; Jimenez D9 ; Monreal M10 ; Vaduganathan M11 ; Fanikos J12 ; Dixon DL3, 8 Show All Authors
Authors
  1. Talasaz AH1, 2, 3
  2. Sadeghipour P4
  3. Aghakouchakzadeh M1
  4. Dreyfus I5
  5. Kakavand H1
  6. Ariannejad H2
  7. Gupta A5, 6, 7
  8. Madhavan MV5, 6
  9. Van Tassell BW3, 8
  10. Jimenez D9
  11. Monreal M10
  12. Vaduganathan M11
  13. Fanikos J12
  14. Dixon DL3, 8
  15. Piazza G11
  16. Parikh SA5, 6
  17. Bhatt DL11
  18. Lip GYH13, 14
  19. Stone GW6, 15
  20. Krumholz HM7, 16, 17
  21. Libby P11
  22. Goldhaber SZ11
  23. Bikdeli B6, 7, 11
Show Affiliations
Authors Affiliations
  1. 1. Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Pharmacotherapy and Outcome Science, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, United States
  4. 4. Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
  5. 5. NewYork-Presbyterian Hospital/Columbia University Irving Medical Center, New York, NY, United States
  6. 6. Clinical Trials Center, Cardiovascular Research Foundation, New York, NY, United States
  7. 7. Center for Outcomes Research and Evaluation (CORE), Yale School of Medicine, New Haven, CT, United States
  8. 8. Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, United States
  9. 9. Respiratory Department, Hospital Ramon y Cajal and Medicine Department, Universidad de Alcala (Instituto de Ramon y Cajal de Investigacion Sanitaria), Centro de Investigacion Biomedica en Red de Enfermedades Respiratorias, Madrid, Spain
  10. 10. Department of Internal Medicine, Hospital Universitari Germans Trials i Pujol, Universidad Catolica San Antonio de Murcia, Barcelona, Spain
  11. 11. Division of Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
  12. 12. Department of Pharmacy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States
  13. 13. Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, University of Liverpool, Liverpool, United Kingdom
  14. 14. Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
  15. 15. Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States
  16. 16. Department of Health Policy and Administration, Yale School of Public Health, New Haven, CT, United States
  17. 17. Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States

Source: Journal of the American College of Cardiology Published:2021


Abstract

Coronavirus disease-2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multiorgan manifestations. Lipid-modulating agents may be useful in treating patients with COVID-19. These agents may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory response and endothelial activation. In addition, dyslipidemia with lower high-density lipoprotein cholesterol and higher triglyceride levels portend worse outcomes in patients with COVID-19. Upon a systematic search, 40 randomized controlled trials (RCTs) with lipid-modulating agents were identified, including 17 statin trials, 14 omega-3 fatty acids RCTs, 3 fibrate RCTs, 5 niacin RCTs, and 1 dalcetrapib RCT for the management or prevention of COVID-19. From these 40 RCTs, only 2 have reported preliminary results, and most others are ongoing. This paper summarizes the ongoing or completed RCTs of lipid-modulating agents in COVID-19 and the implications of these trials for patient management. © 2021 American College of Cardiology Foundation
Experts (# of related papers)
Other Related Docs
16. Effects of Statins on Renin–Angiotensin System, Journal of Cardiovascular Development and Disease (2021)
19. Immune-Based Therapeutic Approaches in Covid-19, Biomedicine and Pharmacotherapy (2022)
24. Statins: Beneficial Effects in Treatment of Covid-19, Advances in Experimental Medicine and Biology (2023)
28. The Role of Lovastatin in the Attenuation of Covid-19, International Immunopharmacology (2021)
30. Potential Therapeutic Options for Covid-19: An Update on Current Evidence, European Journal of Medical Research (2022)
37. Potential Antiviral Immune Response Against Covid-19: Lessons Learned From Sars-Cov, Advances in Experimental Medicine and Biology (2021)